BR112012029131A2 - formulações de longa ação de insulinas - Google Patents

formulações de longa ação de insulinas

Info

Publication number
BR112012029131A2
BR112012029131A2 BR112012029131A BR112012029131A BR112012029131A2 BR 112012029131 A2 BR112012029131 A2 BR 112012029131A2 BR 112012029131 A BR112012029131 A BR 112012029131A BR 112012029131 A BR112012029131 A BR 112012029131A BR 112012029131 A2 BR112012029131 A2 BR 112012029131A2
Authority
BR
Brazil
Prior art keywords
long
acting insulin
insulin formulations
insulin
glargine
Prior art date
Application number
BR112012029131A
Other languages
English (en)
Other versions
BR112012029131B1 (pt
Inventor
Annke Frick
Christiane Fuerst
Isabell Schoettle
Katrin Tertsch
Petra Loos
Peter Boderke
Reinhard Becker
Ulrich Werner
Werner Mueller
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012029131(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012029131A2 publication Critical patent/BR112012029131A2/pt
Publication of BR112012029131B1 publication Critical patent/BR112012029131B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

formulações de longa ação de insulinas. o pedido refere-s a uma formulação farmacêutica aquosa compreendendo 200 a 1000 u/ml [equimolar a 200 a 1000 iu de insulina humana] de insulina glargina, com a condição de que a concentração da referida formulação não seja 684 u/ml de insulina glargina, e seu uso.
BR112012029131-9A 2010-05-19 2011-05-18 Formulação farmacêutica aquosa de longa ação de insulinas e seus usos BR112012029131B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP10305532.3 2010-05-19
EP10305532 2010-05-19
EP10305780.8 2010-07-13
EP10305780 2010-07-13
EP11305140 2011-02-10
EP11305140.3 2011-02-10
PCT/EP2011/058079 WO2011144673A2 (en) 2010-05-19 2011-05-18 Long - acting formulations of insulins

Publications (2)

Publication Number Publication Date
BR112012029131A2 true BR112012029131A2 (pt) 2016-09-13
BR112012029131B1 BR112012029131B1 (pt) 2020-03-10

Family

ID=44148980

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012029131-9A BR112012029131B1 (pt) 2010-05-19 2011-05-18 Formulação farmacêutica aquosa de longa ação de insulinas e seus usos
BR122019006884-4A BR122019006884B1 (pt) 2010-05-19 2011-05-18 Formulações de longa ação de insulinas e seus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019006884-4A BR122019006884B1 (pt) 2010-05-19 2011-05-18 Formulações de longa ação de insulinas e seus usos

Country Status (43)

Country Link
US (11) US20110301081A1 (pt)
EP (9) EP2781212B1 (pt)
JP (5) JP5269945B2 (pt)
KR (4) KR20170072960A (pt)
CN (5) CN103948913A (pt)
AR (1) AR081200A1 (pt)
AU (1) AU2011202239C1 (pt)
BR (2) BR112012029131B1 (pt)
CA (1) CA2792669C (pt)
CL (1) CL2012003197A1 (pt)
CO (1) CO6640217A2 (pt)
CR (1) CR20120578A (pt)
CY (3) CY1115649T1 (pt)
DK (3) DK2387989T3 (pt)
DO (1) DOP2012000261A (pt)
EC (1) ECSP12012298A (pt)
ES (4) ES2509943T3 (pt)
GT (1) GT201200287A (pt)
HK (5) HK1198428A1 (pt)
HR (3) HRP20140860T1 (pt)
HU (2) HUE039355T2 (pt)
IL (2) IL221964A (pt)
JO (2) JO2944B1 (pt)
LT (2) LT2781212T (pt)
MA (1) MA34224B1 (pt)
MX (2) MX343489B (pt)
MY (1) MY156188A (pt)
NI (1) NI201200152A (pt)
NZ (1) NZ602541A (pt)
PE (2) PE20130511A1 (pt)
PH (2) PH12015501421B1 (pt)
PL (4) PL3824876T3 (pt)
PT (3) PT2387989E (pt)
RS (1) RS53559B1 (pt)
RU (3) RU2564104C2 (pt)
SG (2) SG10201510406YA (pt)
SI (3) SI2387989T1 (pt)
TN (1) TN2012000478A1 (pt)
TR (2) TR201809475T4 (pt)
TW (4) TWI469787B (pt)
UY (1) UY33391A (pt)
WO (1) WO2011144673A2 (pt)
ZA (1) ZA201206998B (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
JP5735960B2 (ja) * 2009-07-06 2015-06-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチオニンを含むインスリン製剤
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
JP5950477B2 (ja) 2011-08-10 2016-07-13 アドシア 少なくとも１種の基礎インスリンの注射溶液
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN113730555A (zh) * 2012-01-09 2021-12-03 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
WO2013158277A1 (en) * 2012-04-18 2013-10-24 Waters Technologies Corporation Methods for quantifying polypeptides using mass spectrometry
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
WO2014096985A2 (en) * 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
BR112015013223A2 (pt) * 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
US20220202711A1 (en) * 2013-04-03 2022-06-30 Sanofi Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
ES2709339T3 (es) 2013-04-03 2019-04-16 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
SG10201710347PA (en) * 2013-06-17 2018-01-30 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
AU2015239020A1 (en) 2014-04-04 2016-10-13 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW201623286A (zh) 2014-04-04 2016-07-01 賽諾菲公司 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
CN104688678B (zh) * 2015-02-05 2017-11-17 通化东宝药业股份有限公司 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3337828A1 (en) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
PT3229828T (pt) * 2015-11-10 2023-06-29 Sanofi Aventis Deutschland Formulação de razão fixa de insulina glargina/lixisenatido
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
EP3558341A1 (en) 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
BR112020001617A2 (pt) * 2017-07-27 2020-07-21 Adocia composição sob forma de uma solução aquosa injetável, e, processo de obtenção da insulina humana a21g
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
EP3810183A1 (en) 2018-06-21 2021-04-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220233784A1 (en) 2019-05-29 2022-07-28 Sanofi Drug delivery device
KR20210144609A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
CA3184546A1 (en) 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
KR20230034356A (ko) 2020-07-02 2023-03-09 사노피 활성이 감소된 glp-1r 효능제 펩티드
WO2022034218A1 (en) * 2020-08-14 2022-02-17 Kyon Biotech Ag Increasing the efficacy of biological therapeutic molecules

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CH682806A5 (de) * 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) * 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
PL340255A1 (en) 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2028192A1 (en) 2002-07-04 2009-02-25 Zealand Pharma A/S GLP-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
MXPA05003928A (es) 2003-01-21 2005-06-17 Ortho Tain Inc Un dispositivo dental y un sistema para reducir la cantidad de cooperacion del paciente para tratar una maloclusion utilizando el dispositivo dental.
GB0304822D0 (en) * 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
AU2004216909A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Delivery system for drug and cell therapy
AU2004268648A1 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
JP2007515235A (ja) * 2003-12-22 2007-06-14 ノボ・ノルデイスク・エー／エス 医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
SG151315A1 (en) 2004-03-31 2009-04-30 Centocor Inc Human glp-1 mimetibodies, compositions, methods and uses
WO2007046834A2 (en) 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
ATE518430T1 (de) 2005-10-24 2011-08-15 Nestec Sa Rohfaserformulierung und verfahren zu ihrer verabreichung
BRPI0520704A2 (pt) 2005-11-30 2009-05-19 Generex Pharm Inc formulação farmacêutica absorvida oralmente e método de administração
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
US20090099064A1 (en) 2006-06-08 2009-04-16 Diabecore Medical Inc., Derivatized insulin oligomers
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
WO2008013938A2 (en) * 2006-07-27 2008-01-31 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
CA2697265A1 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
CN101778862B (zh) 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
PL2209800T3 (pl) * 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
CN101951957A (zh) 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
JP5781308B2 (ja) 2008-02-19 2015-09-16 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 異種タンパク質を得る方法およびインスリン類似体
JP2011523052A (ja) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
CN106177958A (zh) 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
KR101759499B1 (ko) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
DK2329848T4 (da) 2009-11-13 2019-09-09 Sanofi Aventis Deutschland Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
JP2013520175A (ja) 2010-02-22 2013-06-06 ケース ウェスタン リザーブ ユニバーシティ 可溶形および結晶形の長時間作用型インスリン類似体製剤
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2011160066A1 (en) 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
KR20140041409A (ko) 2011-02-02 2014-04-04 사노피-아벤티스 도이칠란트 게엠베하 ２형 진성 당뇨병 환자에서 저혈당증의 예방
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
EP2763691A1 (en) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

Also Published As

Publication number Publication date
TR201809514T4 (tr) 2018-07-23
TW201735941A (zh) 2017-10-16
US20190046616A1 (en) 2019-02-14
EP2571517B1 (en) 2018-04-04
US20190388511A1 (en) 2019-12-26
RU2017146048A (ru) 2019-06-27
US20200384087A1 (en) 2020-12-10
GT201200287A (es) 2015-03-09
PT2387989E (pt) 2014-09-15
JP5269945B2 (ja) 2013-08-21
PL2781212T3 (pl) 2018-08-31
KR101913672B1 (ko) 2018-11-01
US20200215163A1 (en) 2020-07-09
PH12015501421A1 (en) 2015-09-07
DK2571517T3 (en) 2018-07-23
AU2011202239C1 (en) 2017-03-16
PL2387989T3 (pl) 2014-12-31
TN2012000478A1 (en) 2014-04-01
CA2792669A1 (en) 2011-11-24
EP2781212B1 (en) 2018-04-04
EP4218723A2 (en) 2023-08-02
HRP20140860T1 (hr) 2014-10-24
JP2011241213A (ja) 2011-12-01
CY1115649T1 (el) 2017-01-04
HUE039354T2 (hu) 2018-12-28
CL2012003197A1 (es) 2013-01-25
CR20120578A (es) 2013-03-04
US20160228516A1 (en) 2016-08-11
MY156188A (en) 2016-01-29
CN103948913A (zh) 2014-07-30
MA34224B1 (fr) 2013-05-02
US20140206611A1 (en) 2014-07-24
HK1248592A1 (zh) 2018-10-19
JO2944B1 (en) 2016-03-15
RU2642662C2 (ru) 2018-01-25
KR101989343B1 (ko) 2019-06-14
ES2676401T3 (es) 2018-07-19
TW201208695A (en) 2012-03-01
EP3424491A1 (en) 2019-01-09
EP3400931A1 (en) 2018-11-14
TWI605825B (zh) 2017-11-21
PH12015501421B1 (en) 2015-09-07
TW201607552A (zh) 2016-03-01
HK1202428A1 (en) 2015-10-02
CY1120407T1 (el) 2019-07-10
KR101486743B1 (ko) 2015-01-28
KR20130040824A (ko) 2013-04-24
EP2387989B1 (en) 2014-07-16
TWI469787B (zh) 2015-01-21
ZA201206998B (en) 2013-05-29
RU2017146048A3 (pt) 2021-07-01
UY33391A (es) 2011-10-31
BR122019006884B1 (pt) 2022-08-23
US20110301081A1 (en) 2011-12-08
PT2571517T (pt) 2018-07-10
SI2781212T1 (en) 2018-08-31
RU2015132860A (ru) 2017-02-09
EP4218723A3 (en) 2023-11-08
ES2945208T3 (es) 2023-06-29
IL221964A (en) 2017-04-30
AU2011202239B2 (en) 2012-06-07
ES2690302T3 (es) 2018-11-20
DK2781212T3 (en) 2018-07-23
DK2387989T3 (da) 2014-10-20
JP6333775B2 (ja) 2018-05-30
EP2781212A1 (en) 2014-09-24
TR201809475T4 (tr) 2018-07-23
HK1210435A1 (en) 2016-04-22
SG185593A1 (en) 2012-12-28
HK1198428A1 (en) 2015-04-24
IL251318B (en) 2018-12-31
MX2019003693A (es) 2019-07-04
KR20170072960A (ko) 2017-06-27
EP3824876A1 (en) 2021-05-26
KR20140109515A (ko) 2014-09-15
EP3607935A1 (en) 2020-02-12
SG10201510406YA (en) 2016-01-28
RU2564104C2 (ru) 2015-09-27
LT2571517T (lt) 2018-07-25
PL2571517T3 (pl) 2018-09-28
PE20130511A1 (es) 2013-05-02
RS53559B1 (en) 2015-02-27
US20160339084A1 (en) 2016-11-24
IL251318A0 (en) 2017-05-29
HRP20181028T1 (hr) 2018-08-24
ES2509943T3 (es) 2014-10-20
TWI496580B (zh) 2015-08-21
EP3824876B8 (en) 2023-08-02
CY1121042T1 (el) 2019-12-11
PL3824876T3 (pl) 2024-02-19
PT2781212T (pt) 2018-07-10
HRP20181026T1 (hr) 2018-08-24
US20120122774A1 (en) 2012-05-17
DOP2012000261A (es) 2013-01-31
HUE039355T2 (hu) 2018-12-28
CN102319422A (zh) 2012-01-18
JOP20150245B1 (ar) 2021-08-17
ECSP12012298A (es) 2012-12-28
NZ602541A (en) 2013-11-29
JP2018044003A (ja) 2018-03-22
SI2571517T1 (en) 2018-08-31
LT2781212T (lt) 2018-07-25
MX343489B (es) 2016-11-08
CN107583038A (zh) 2018-01-16
US9345750B2 (en) 2016-05-24
HK1248593A1 (zh) 2018-10-19
BR112012029131B1 (pt) 2020-03-10
PH12019500517A1 (en) 2020-03-02
JP2020040990A (ja) 2020-03-19
KR20180088752A (ko) 2018-08-06
NI201200152A (es) 2013-01-24
CA2792669C (en) 2015-09-29
MX2012011278A (es) 2012-11-06
CO6640217A2 (es) 2013-03-22
EP2387989A3 (en) 2012-04-18
RU2011119988A (ru) 2012-11-27
TW201427684A (zh) 2014-07-16
AR081200A1 (es) 2012-07-04
EP2387989A2 (en) 2011-11-23
WO2011144673A2 (en) 2011-11-24
US20210308225A1 (en) 2021-10-07
EP3824876B1 (en) 2023-02-22
CN107583037A (zh) 2018-01-16
PE20160781A1 (es) 2016-08-26
WO2011144673A3 (en) 2012-05-03
JP2015172068A (ja) 2015-10-01
EP3636250A1 (en) 2020-04-15
AU2011202239A1 (en) 2011-12-08
US20150164999A1 (en) 2015-06-18
JP2013147509A (ja) 2013-08-01
EP2571517A2 (en) 2013-03-27
SI2387989T1 (sl) 2014-10-30
CN104622788A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
BR112012029131A2 (pt) formulações de longa ação de insulinas
UY32764A (es) Preparaciones insulinicas que comprenden metionina
UY32765A (es) Preparaciones insulinicas de accion lenta
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
BR112013000537A2 (pt) composição aquosa contendo bromexina
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
BR112015024659A2 (pt) tratamento de diabetes mellitus por formulações de ação prolongada de insulinas
AR082422A1 (es) Composicion detergente liquida
AR092840A1 (es) Elaboracion de degarelix
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
CL2013000771A1 (es) Formulacion acuosa estable que comprende polipeptido del factor estimulante de colonias de granulocitos bovino (bg-csf); liofilizado de la preparacion; proceso para preparar la formulación; uso para tratar infección en un animal.
UA110935C2 (uk) Препарат інсуліну пролонгованої дії
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico
BRPI0903616B8 (pt) formulação farmacêutica contendo flagelina co-administrada e/ou fusionada a um peptídeo (p10) e seu uso
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon
UA104448C2 (uk) Застосування 20 % настойки яглиці звичайної на 70 % спирту етиловому як засобу з гіпоглікемічною дією

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2011, OBSERVADAS AS CONDICOES LEGAIS.